Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2018-06-20
2071-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The 'Swiss registry for neuromuscular disorders' (Swiss-Reg-NMD) collects medical information from people with neuromuscular disorders. It is led by specialized physicians from all over Switzerland and located at the Institute of Social and Preventive Medicine (ISPM) in Bern. The registry includes children and adults living or treated in Switzerland who are diagnosed with Duchenne-Becker Muscular Dystrophy (DMD/BMD), Spinal Muscular Atrophy (SMA) and merosin-deficient muscular dystrophy also called LAMA2-related muscular dystrophy (MDC1A respectively LAMA2).
The Swiss Registry for neuromuscular disorders was initially founded in 2008 to give Swiss patients with a neuromuscular disease access to new therapies. In 2018, the registry was reorganized to meet new legal requirements and expectations of patients and research organizations. The Swiss Ethics Commission approved the project (project ID: 2018-00289, observational study, risk category A).
NMDs are rare diseases with few patients scattered across the country. A national patient registry with a centralized registration facilitates the participation of Swiss patients in therapeutic trials and the creation of Swiss trial sites.
Objectives:
Primary objectives of the Swiss-Reg-NMD project are:
1. Establish a representative population-based Swiss cohort of children, adolescents and adults with NMDs
2. Provide epidemiological data to investigate the incidence, prevalence, spectrum of diagnosis, survival rates and mortality of NMDs in Switzerland
3. Provide a platform for clinical research:
1. Offer a resource to recruit Swiss patients in current and future national and international therapeutic trials or observational studies
2. Offer a resource to facilitate the establishment of therapeutic trial sites in Switzerland
3. Answer questions in the following areas: health, health care, social-, educational-, professional-, economic aspects, and quality of life
4. Offer a resource for post-marketing surveillance (effects and side effects of therapies/treatments)
4. Provide a platform for communication:
1. Promote the exchange of knowledge between clinics, researchers, therapists and national and cantonal health authorities in particular regarding standards of care
2. Facilitate national and international collaborations, in particular with the international registry of TREAT-NMD and the upcoming Swiss Registry for Rare Diseases
Inclusion/exclusion criteria:
All children, adolescents and adults living or treated in Switzerland who are diagnosed with a NMD. The diagnosis needs to be confirmed, whenever possible, by genetic testing, or at least by biopsy and/or electroneuromyography, according to international standards for the diagnosis of the given NMD. Once the diagnosis is established, there is no specific exclusion criteria.
Currently, patients with SMA, DMD/BMD, merosin-deficient muscular dystrophy also called LAMA2-related muscular dystrophy (MDC1A respectively LAMA2) and Collagen 6 related muscular dystrophy are included.
Procedure:
After a NMD diagnosis, the treating physician informs the patient and the parents (if the patient is still a child) during a consultation in a clinic or practice in writing and orally about the Swiss-Reg-NMD. The patient/parents who wish to participate sign the consent form and the patient is registered in the Swiss-Reg-NMD. If the patient/parents do not wish to participate, only a minimal anonymous data set is recorded.
The following data will be collected:
* Medical data
* Data from questionnaires for patients and families
* Data from links to routine statistics and other medical registries
Clinical data (report of new cases and follow-up reports): NMD subtype, severity, and associated conditions; Comorbidities; Medical care and medication; Therapies; (Serious) adverse events; Hospitalisations; Motor Function Assessments; Socio-demographic characteristics.
Questionnaire data: We will collect data through questionnaires with a focus on (but not exclusively):
* Health related questions like nutrition, sleep, pain
* Health behaviours (e.g., physical activity, smoking)
* Medical equipment use (type, usage, satisfaction)
* Treatments and therapies: frequency, intensity, start, types
* Quality of life and participation (involvement in a life situation)
* Social-economic factors
* Education (early childhood education, school, professional integration)
* Patient/caregiver reported outcomes
* Needs and concerns of persons with NMDs and their families
Routine data and linkages: e.g. Federal Statistical Office (e.g. birth registry, cause of death statistics, hospital statistics); Swiss National Cohort (socioeconomic data, family information); other medical registries (e.g. rare disease registry); Communities of residence (vital status, date of death, address).
Funding:
Schweizerische Muskelgesellschaft; ASRIMM, Association Suisse Romande Intervenant contre les Maladies neuromusculaire; MGR, Associazione malattie genetiche rare della svizzera italiana; fsrmm, schweizerische stiftung für die erforschung der muskelkrankheiten; SMA Schweiz; Duchenne Schweiz; Avexis; Biogen; Novartis; Pfizer, PTC Therapeutics; Roche; Sarepta.
Data protection:
Data generation, transmission, storage and analysis of health related personal data within this project will follow strictly the current Swiss legal requirements for data protection. Data analyses will always be done using pseudonymised datasets. Health related personal data captured during this project are strictly confidential. Project data shall be handled with uttermost discretion and only be accessible to authorized personnel. Direct access to source documents will be permitted for purposes of monitoring, audits or inspections. The data protection concept of ISPM ensures the secure handling of all sensitive data at ISPM and within Swiss-Reg-NMD. The Swiss-Reg-NMD team is responsible for the implementation and compliance with the confidentiality and data security measures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient population
Children, adolescents and adults diagnosed with a NMD (DMD/BMD/IMD; SMA; COL-6; LAMA-2) who are treated or living in Switzerland.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who are living or treated for a NMD in Switzerland, and
* Who gave informed consent
Exclusion Criteria
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Children's Hospital Basel
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
University of Lausanne Hospitals
OTHER
Ente Ospedaliero Cantonale, Bellinzona
OTHER
University Children's Hospital, Zurich
OTHER
University of Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudia E Kuehni, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Social and Preventive Medicine (ISPM), University of Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Institute of Southern Switzerland, Ospedale San Giovanni
Bellinzona, Canton Ticino, Switzerland
Neuro Centre of Italian Switzerland, Ospedale Regionale di Lugano
Lugano, Canton Ticino, Switzerland
University Hospital Lausanne CHUV, Children's Hospital
Lausanne, Vaude, Switzerland
University Hospital Lausanne CHUV
Lausanne, Vaude, Switzerland
University Children's Hospital Basel
Basel, , Switzerland
University Hospital Basel
Basel, , Switzerland
Inselspital Bern, Children's Hospital
Bern, , Switzerland
Inselspital Bern
Bern, , Switzerland
Institute of Social and Preventive Medicine (ISPM), University of Bern
Bern, , Switzerland
University Hospitals of Geneva, Children's Hospital
Geneva, , Switzerland
University Hospitals of Geneva
Geneva, , Switzerland
Cantonal Hospital of Lucerne LUKS
Lucerne, , Switzerland
Private Practice Alpenquai
Lucerne, , Switzerland
Cantonal Hospital of Eastern Switzerland
Sankt Gallen, , Switzerland
Children's Hospital of Eastern Switzerland
Sankt Gallen, , Switzerland
University Hospital Zuerich, Children's Hospital
Zurich, , Switzerland
University Hospital Zuerich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gian Paolo Ramelli, Prof.
Role: primary
Paolo Ripellino, Dr.med.
Role: primary
David Jacquier, Dr.
Role: primary
Stefano Carda, Dr.
Role: primary
Andrea Klein, Prof. Dr.
Role: primary
Janina Wendebourg, Dr.
Role: primary
Andrea Klein, Prof. Dr.
Role: primary
Olivier Scheidegger, PD Dr.
Role: primary
Claudia E Kuehni, Prof. MD
Role: primary
Joel Fluss, PD Dr.
Role: primary
Agustina Lascano, PD Dr.
Role: primary
Sandra Bigi, PD Dr.
Role: primary
Petra Kolditz, Dr.med.
Role: primary
Christoph Neuwirth, PD Dr.
Role: primary
Philip Broser, PD Dr.
Role: primary
Georg Stettner, PD Dr.
Role: primary
Hans Jung, Prof.Dr.med.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Website of the registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-00289
Identifier Type: -
Identifier Source: org_study_id